We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




NonInvasive Device Monitors People with Diabetes

By LabMedica International staff writers
Posted on 05 Aug 2015
Print article
Image: The noninvasive Glucosense monitor for blood glucose levels in diabetics (Photo courtesy University of Leeds).
Image: The noninvasive Glucosense monitor for blood glucose levels in diabetics (Photo courtesy University of Leeds).
A new laser sensor that monitors blood glucose levels without penetrating the skin could transform the lives of millions of people living with diabetes.

Currently, many people with diabetes need to measure their blood glucose levels by pricking their fingers, squeezing drops of blood onto test strips, and processing the results with portable glucometers, but the process can be uncomfortable, messy and often has to be repeated several times every day.

The new technology developed by team at the University of Leeds (UK) uses a small device with low-powered lasers to measure blood glucose levels without penetrating the skin and could give people a simpler, pain-free alternative to finger pricking. The technology has continuous monitoring capabilities making it ideal for development as a wearable device. This could help improve the lives of millions of people by enabling them to constantly monitor their glucose levels without the need for an implant.

At the heart of the new technology is a piece of nano-engineered silica glass with ions that fluoresce in infrared light when a low power laser light hits them. When the glass is in contact with the users' skin, the extent of fluorescence signal varies in relation to the concentration of glucose in their blood. The device measures the length of time the fluorescence lasts for and uses that to calculate the glucose level in a person's bloodstream without the need for a needle. This process takes less than 30 seconds.

The technology is licensed to Glucosense Diagnostics Ltd, (London, UK), a spin-out company jointly formed and funded by the University of Leeds and NetScientific plc (London, UK), a biomedical and healthcare technology group specializing in commercializing transformative technologies from leading universities and research institutes.

Peter J. Grant, MBChB, MD, FRCP, FESC, a professor of medicine and consultant diabetes specialist, said, “Non-invasive monitoring will be particularly valuable in young people with Type 1 diabetes. Within this group, those who are attempting very tight control such as young women going through pregnancy or people who are experiencing recurrent hypoglycemia could find this technology very useful.”

Related Links:

University of Leeds
Glucosense Diagnostics Ltd. 
NetScientific plc 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.